Profile
| Role | Insider |
|---|---|
| Notability | 10/100 |
Board memberships
- Axsome Therapeutics, Inc.
Updated Jul 16, 2026
Coleman Mark has filed 3 SEC Form 4 filings across 1 company in the last 90 days — active on both sides. Lifetime open-market purchases: $200K. Lifetime open-market sales: $8.21M. Historical track record: 1/5 stars across 3 tracked purchases.
| Role | Insider |
|---|---|
| Notability | 10/100 |
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★☆☆☆☆ (1/5) |
|---|---|
| Total purchases tracked | 3 |
| Purchases with forward-return data | 3 |
| 30-day win rate | 0% |
| 90-day win rate | 10000% |
| Avg 5-day return | -967.98% |
| Avg 30-day return | -818.32% |
| Avg 90-day return | +1413.10% |
| Best 30-day return | -818.32% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-11 | AXSM | Axsome Therapeutics, Inc. | S — Open-market sale | 643 | $249.00 | $160K |
| 2026-06-11 | AXSM | Axsome Therapeutics, Inc. | M — Option exercise | 1.4K | — | |
| 2026-06-02 | AXSM | Axsome Therapeutics, Inc. | S — Open-market sale | 5.5K | $223.39 | $1.24M |
| 2026-06-02 | AXSM | Axsome Therapeutics, Inc. | S — Open-market sale | 6.0K | $230.30 | $1.38M |
| 2026-06-02 | AXSM | Axsome Therapeutics, Inc. | S — Open-market sale | 6.0K | $233.46 | $1.40M |
| 2026-02-28 | AXSM | Axsome Therapeutics, Inc. | S — Open-market sale [10b5-1] | 25.0K | $161.11 | $4.03M |
| 2026-02-26 | AXSM | Axsome Therapeutics, Inc. | M — Option exercise | 6.2K | $4.95 | $31K |
| 2026-02-24 | AXSM | Axsome Therapeutics, Inc. | M — Option exercise | 12.5K | $4.95 | $62K |
| 2026-02-11 | AXSM | Axsome Therapeutics, Inc. | M — Option exercise | 5.2K | $8.02 | $42K |
| 2025-09-08 | AXSM | Axsome Therapeutics, Inc. | P — Open-market purchase | 488 | $127.40 | $62K |
| 2025-09-08 | AXSM | Axsome Therapeutics, Inc. | P — Open-market purchase | 287 | $127.30 | $37K |
| 2025-09-08 | AXSM | Axsome Therapeutics, Inc. | P — Open-market purchase | 800 | $127.20 | $102K |
| 2024-11-20 | AXSM | Axsome Therapeutics, Inc. | M — Option exercise | 33.4K | $5.94 | $198K |
Coleman Mark is a corporate insider — currently tracked as Insider of Axsome Therapeutics, Inc. (AXSM). InsiderAlpha tracks every SEC Form 4 filing in real time.
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 3 open-market purchases ($200K) and 5 open-market sales ($8.21M) across all tracked filings.
Across 3 tracked purchases, Coleman Mark averaged -818.3% avg 30-day return with a 0% 30-day win rate. InsiderAlpha rates the track record at 1/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Coleman Mark profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.